Facebook
Twitter
LinkedIn

Newsletter

NCI SBIR Offers Funding Opportunities for Innovative Small Businesses Developing Novel Cancer Techno
Facebook
Twitter
LinkedIn

BayBio is committed to supporting valuable resources like the National Cancer Institute’s Small Business Innovation Research (NCI SBIR) Development Center, as they both provide seed funding to and attract additional investment in Bay Area companies. The SBIR & STTR (Small Business Technology Transfer) Programs are government set-asides that fund domestic small businesses engaged in research and development with the potential for commercialization and public benefit.

One funding opportunity we would like to highlight is NCI SBIR’s newly released FY2013 contract topics solicitation. Thirteen funding opportunities provide $10 million in early-stage financing to drive innovation in emerging technology areas of interest to NCI including, but not limited to: therapeutics, diagnostics, nanotechnology, research tools, health information technology, imaging technologies, and radiation therapy. For a full list of NCI contract funding opportunities, please visit: http://sbir.cancer.gov/funding/contracts/.

These contract topics lend themselves to ground-breaking solutions based on strong scientific and market needs. Applications for the FY2013 contract topics are due by 5 p.m. ET on Tuesday, November 13, 2012, and proposals are only accepted once per year. Click here to download the FY2013 SBIR contract solicitation.

NCI has been involved in more than 70 percent of the anticancer therapeutics on the market today and is working diligently to support the next generation of cancer technologies. Entrepreneurs and small businesses are encouraged to explore contract funding opportunities, grant funding opportunities, and the numerous resourcesand programs available to SBIR & STTR awardees. The NCI SBIR & STTR Programs provide a range of incentives for small businesses to consider.

  • SBIR & STTR awards provide recognition, visibility, and validation
  • Funding can be leveraged to attract additional funding from third-party investors
  • Awards are not loans; no repayment is required
  • SBIR & STTR funding is non-dilutive capital and does not impact the company’s stock or shares in any way
  • Projects are vetted through NIH’s rigorous scientific peer review
  • Intellectual property rights to technologies developed under these programs are retained by the small business concern
  • Awardees are offered opportunities to connect with investors and apply for programs such as the NCI SBIR Investor Forum and the Bridge Award, a $3 million dollar funding opportunity to advance SBIR projects toward commercialization.

For more information about the NCI SBIR Development Center and the programs they support, visit:http://sbir.cancer.gov or follow @NCIsbir on Twitter for updates on funding opportunities, events, and other initiatives.